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Supplemental Experimental Procedures
Expression and purification of recombinant ESCRT-I proteins -Expression was done in C41(DE3)RIPL E. coli. Cells (6 L) were grown at 37 °C in 2XTY medium containing 100 µg/mL ampicillin to an optical density of 0.8 at 600 nm. Expression was induced with 1 mM IPTG. After induction, cells were incubated over-night at 12 °C, then pelleted by centrifugation at 4000 g. The pellets were resuspended in 160 ml of buffer W1 (20 mM Tris pH8.0 (4 °C), 50 mM potassium phosphate pH 8.0 (4 °C), 100 mM NaCl, 15 mM imidazole, 0.05% Triton X-100, 1 mM TCEP). Cells were lysed by pulsed sonication for 10 minutes. The lysate was ultracentrifuged at 95000 g for 45 min and passed through a 0.2 µm filter before loading on a HisPrep™ FF 16/10
Column (GE Healthcare) equilibrated in buffer W1. The column was washed with buffer W1, followed by the buffer W2 (same as W1 but without Triton X-100) and eluted with 400 mM imidazole in buffer W2. Fractions containing the four ESCRT-I subunits were pooled and loaded on a 5 mL Hitrap heparin HP column coupled to two tandem 5 ml Hitrap Q columns (GE Healthcare) equilibrated with buffer A (20 mM Tris pH 6.8 (20 °C), 1 mM DTT). The complex is not retained on the heparin column but binds the Q-resin. The coupled columns were washed with 1 volume of buffer A before the heparin column was removed. Protein was eluted from the Q column using a 12 column volume gradient of 0-100% buffer B (20 mM Tris pH6.8
(20 °C), 1 M NaCl, 1 mM DTT). Fractions were analyzed on SDS-PAGE, and those containing a 1:1:1:1 stoichiometric ratio of the 4 subunits were pooled and concentrated to a volume of 2 mL using a 10 kDa MWCO Amicon Ultra-15 concentrator (Millipore). Concentrated proteins were loaded on a HiLoad 16/60
Superdex 200 column (GE Healthcare) equilibrated in 20 mM Tris-HCl pH 7.5, 100
mM NaCl, 2 mM DTT. Fractions corresponding to a tetrameric ESCRT-I complex containing UBAP1 were pooled and concentrated to 12.9 mg/ml.
Expression and purification of SOUBA -Expression was done as described above, except that the cells were induced at OD 600nm of 0.9 for 4 hours at 37 °C. Following purification on a Ni-resin, fractions containing the SOUBA domain were pooled and subjected to TEV cleavage at mass ratio (TEV/protein) of 1/30 overnight at 4 °C in order to remove the N-terminal 6His-tag. The cleaved product was passed through a HisTrap™ FF 5 mL to separate it from the 6His-labelled TEV protease and then loaded on a 5 ml Hitrap Q columns (GE Healthcare) equilibrated with buffer A (20 mM Tris pH 8, 1 mM DTT). Protein was eluted from the Q column, using a 10 column volume gradient of 0-100% buffer B (20 mM Tris pH 8, 1 M NaCl, 1 mM DTT).
Fractions containing the protein were concentrated and loaded on a HiLoad 16/60
Superdex 75 column (GE Healthcare) equilibrated in 20 mM Tris-HCl pH 7.5, 100
mM NaCl, 2 mM DTT. SDS-PAGE of the fractions showed a pure 13.5 kDa band corresponding to the SOUBA domain, which was pooled and concentrated to 21 mg/ml.
Seleno-methionine substituted protein was grown in methionine-requiring B834(DE3) cells. Pre-cultures grown in 2XTY medium containing 100 μg/mL ampicillin were used to inoculate M9 minimal medium supplemented with 0.4 % w/v glucose, 100 µg/mL ampicillin, 2 mM MgSO4, 25µg/mL w/v FeSO4, 1µg/mL Riboflavin, 1µg/mL Niacinamide, 0.1µg/mL pyridoxine monohydrochloride, 1µg/mL thiamine), 0.04 mg/ml of each amino acid except methionine and 0.04 mg/ml seleno-L-methionine. After ~10 hrs at 37°C the cultures were induced with 1 mM IPTG and incubated for an additional 4 hours at 37 °C before harvesting. Subsequent purification proceeded as for unlabeled protein.
Crystallization of the SOUBA domain -Seleno-methionine crystals of the human SOUBA domain (UBAP1 389-502) with the K415A, K416A and E418A triple mutation designed to reduce surface enthropy charge (using SERp server:
http://services.mbi.ucla.edu/SER/) were grown by mixing 0.2 µL of the concentrated protein with 0.2 µL of a solution containing 645 mM Na/K tartrate, 271 mM LiSO4, 100 mM CHES pH 9.5, 2 mM TCEP, 5% glycerol, and 0.1 µL of seeds from native crystals obtained in similar conditions. The crystals grew in space group P1 with unit cell dimensions given in Table 1 . Data collection and refinement were carried out as described in Supplementary experimental procedures.
Crystallographic data collection and refinement -The diffraction data were collected at ESRF BM30 using a selenomethionine-substituted crystal and SAD methodology (Table 1) . Sites for 7 selenomethionines were located using HySS and refined with SOLVE (Zwart et al., 2008 ). An initial model for the domain was generated using
RESOLVE. This initial model was manually adjusted with COOT (Emsley and Cowtan, 2004) and refinement was carried out using PHENIX. Data collection and refinement statistics are given in Table 1 . There are two molecules in the asymmetric unit that are related by a non-crystallographic two-fold axis. The two molecules in the asymmetric unit are linked to each other through a disulfide bond between two-fold related copies of residue Cys452. The structure shows density for two oxidized selenomethionines.
Purification of diubiquitins -K48-linked and K63-linked diubiquitins were prepared as described previously (Dong et al., 2011) .
Expression and purification of paramagnetically labelled monoubiquitin -Wild-type monoubiquitin cloned into a modified pRSETa (Invitrogen) vector was mutated using a Quickchange mutagenesis kit to generate the following clones: K6C, D39C, K48C
and S57C. The proteins were expressed in C41 cells and purified using ammonium sulphate precipitation, acid denaturation and gel filtration, and were kept in a reduced state throughout by using buffers containing 10 mM DTT. The mutant ubiquitins were passed though a NAP10 column to remove the DTT and immediately labeled by incubation with a 100-fold molar excess of 3-(2-iodoacetamido)-PROXYL (SigmaAldrich). The reaction was allowed to proceed for 12 h at room temperature before the excess label was removed using a NAP10 column. To obtain spectra of chemically modified but not paramagnetic samples, spin-labeled samples were reduced by the addition of 10 mM ascorbic acid. All paramagnetic and chemically modified but non-paramagnetic ubiquitin samples were dialysed into PBS buffer prior to use.
Coprecipitation Assays -293T cells were transfected with GST, HA and myc expression vectors (1 g of each) using polyethylenimine (Polysciences, Inc). 36 hr later, cells were harvested and lysed in 1 ml of 50 mM Tris.HCl, pH 7.4; 150 mM NaCl; 5 mM EDTA; 5% glycerol; 1% Triton X-100 and a protease inhibitor cocktail (complete mini-EDTA free, Roche). Clarified lysates were incubated with glutathionesepharose beads (GE Healthcare) for 3 hr at 4 ºC and washed three times with wash buffer (50 mM Tris.HCl, pH 7.4; 150 mM NaCl; 5 mM EDTA; 5% glycerol; 0.1% Triton X-100). The bead-bound proteins were eluted by boiling in 100 μl of sodium dodecyl sulfate sample buffer and analyzed by western blotting with anti-HA monoclonal antibody. The same approach was followed for coprecipitation of proteins fused to
One-strep tag with the difference that clarified lysates from cells stably expressing the tagged proteins were incubated with Strep-Tactin superflow plus (Qiagen).
Multinucleation Assays -HeLa cells (25000) were seeded in a 48 well plate and 2 hr after plating were transfected with 50 pmol of siRNA targeting either Luciferase, UBAP1 or hIST1 using Dharmafect-1 (Dharmacon). 48 hr later cells were reseeded onto glass coverslips and transfected again with 50 pmol of siRNA for another 48 hr.
After RNAi treatment, cells were fixed with 3% paraformaldehyde for 15 min, permeabilised with PBS/0.1% Triton X-100 for 5 min and then stained with monoclonal anti-Tubulin in PBS/1% BSA for 2 hr. Alexa594 conjugated secondary antibody was applied in PBS for 1 hr. Nuclei were visualized using Hoechst 33258
and coverslips were mounted in Mowiol. Images were taken using a Leica AOBS SP2 confocal microscope. 300 cells per coverslip were scored for the presence of
